Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03308201 | Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer | completed | Phase 1 | 55 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06290466 | Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects | completed | Phase 1 | 18 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02476539 | Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | completed | Phase 1 | 28 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT02527746 | Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | completed | Phase 1 | 18 | EVIVE BiotechnologyINDUSTRY | 0 | Feb 23, 2024 | clinicaltrials |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03255070 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | completed | Phase 1 | 106 | Ambrx, Inc.INDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT03012230 | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
| NCT03471663 | A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer | completed | Phase 1 | 200 | InventisBio Co., LtdINDUSTRY | 2 | Jan 8, 2024 | clinicaltrials |
| NCT04983238 | Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | completed | Phase 1 / Phase 2 | 48 | Byondis B.V.INDUSTRY | 3 | Jan 5, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT03052634 | A Study of RC48-ADC in Subjects With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 112 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04431674 | Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Breast Cancer(USmBRT-B) | completed | Phase 1 | 20 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02754011 | Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative(GEP14-LEECAP) | completed | Phase 1 | 18 | UNICANCEROTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01300962 | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | completed | Phase 1 | 47 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04150731 | 16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer | completed | Phase 1 / Phase 2 | 8 | University of AarhusOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02672475 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | completed | Phase 1 | 29 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05519059 | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | completed | Phase 1 | 15 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03481998 | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 104 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03054363 | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00634634 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02599363 | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03304210 | PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer(PIPAC-nabpac) | completed | Phase 1 | 20 | University Hospital, GhentOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01717261 | Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer(SPORT) | completed | Phase 1 | 10 | Maisonneuve-Rosemont HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03840200 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 5 | Oct 30, 2023 | clinicaltrials |
| NCT00944528 | Single Dose Partial Breast Radiotherapy(RSU) | completed | Phase 1 | 35 | Duke UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | completed | Phase 1 | 105 | Syros PharmaceuticalsINDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02254005 | Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer | completed | Phase 1 | 24 | Boehringer IngelheimINDUSTRY | 0 | Oct 24, 2023 | clinicaltrials |
| NCT06098599 | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer | completed | Phase 1 | 48 | Luye Pharma Group Ltd.INDUSTRY | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06074757 | Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study | completed | Phase 1 | 48 | Kashiv BioSciences, LLCINDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00082641 | Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04367090 | Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | completed | Phase 1 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03953833 | B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer(B003-101) | completed | Phase 1 | 30 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion(MpeTK01) | completed | Phase 1 | 19 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02649686 | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03941743 | Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer | completed | Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00003927 | Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2024source: clinicaltrials